Log In
BCIQ
Print this Print this
 

IMP321 (formerly ImmuFact IMP321)

  Manage Alerts
Collapse Summary General Information
Company Prima BioMed Ltd.
DescriptionSoluble recombinant fusion protein consisting of an Fc portion of a human Ig and a dimeric protein with 4 extracellular domains of lymphocyte-activation gene 3 (LAG3; CD223)
Molecular Target Major histocompatibility complex class II (MHCII) ; Lymphocyte-activation gene 3 (LAG3) (CD223)
Mechanism of ActionImmune modulation
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$28.0M

$10.8M

$7.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/17/2014

$28.0M

$10.8M

$7.2M

10/14/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today